Mazdutide 10 mg

DRAGON PHARMA MAZDUTIDE

Dragon Pharma Mazdutide 10mg represents the cutting edge of metabolic peptide therapeutics, delivering a first-in-class dual GLP-1 and GIP receptor agonist in a pharmaceutical-grade 10mg formulation. Mazdutide (also known as LY3305677) is a novel 39-amino-acid peptide engineered to simultaneously activate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, creating synergistic metabolic effects that surpass single-receptor agonists like semaglutide or tirzepatide. This lab-verified 9.11mg potency formulation offers athletes, bodybuilders, and fitness enthusiasts a powerful tool for optimizing body composition, enhancing metabolic health, and achieving unprecedented weight management results. For competitors preparing for shows, individuals seeking to overcome weight loss plateaus, or those pursuing metabolic optimization alongside performance enhancement, Mazdutide represents a revolutionary advancement in peptide-based body composition management.

DRUG COMPOSITION

Each 2mL vial contains 10mg of Mazdutide (LY3305677), a synthetic 39-amino-acid peptide with the sequence based on exendin-4 backbone with strategic modifications for dual receptor activity. The molecular formula is C₁₈₇H₂₉₁N₅₅O₅₉S with a molecular weight of 4290.8 g/mol. Dragon Pharma utilizes advanced recombinant DNA technology and solid-phase peptide synthesis to produce Mazdutide with ≥95% purity verified by HPLC-MS. Independent laboratory analysis confirms 9.11mg actual content (91.1% of labeled 10mg), demonstrating consistent manufacturing within pharmaceutical specifications. The lyophilized powder contains no preservatives, stabilizers, or bacterial endotoxins. The peptide incorporates Aib (α-aminoisobutyric acid) substitutions at positions 2 and 14 to resist DPP-4 degradation, C-terminal amidation for stability, and strategic amino acid modifications that confer balanced GLP-1 and GIP receptor agonism with approximately 5:1 GLP-1:GIP potency ratio.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized powder in a 2mL Type I borosilicate glass vial with fluoropolymer-coated bromobutyl rubber stopper and aluminum crimp seal. The powder exhibits moderate solubility in bacteriostatic water, requiring 60-90 seconds of gentle swirling to dissolve completely into a clear, colorless to slightly opalescent solution. The 10mg concentration represents the optimal balance between dosing convenience and solution stability. Lyophilization parameters are specifically optimized for this large peptide (39 amino acids) to prevent aggregation and maintain conformational integrity. Each batch undergoes rigorous testing for fibrillation potential, oxidation, and related substances to ensure consistent biological activity. The formulation includes a slight molar excess of hydrochloric acid to maintain optimal pH during reconstitution and storage.

PHARMACEUTICAL GROUP AND ATC CODE

Mazdutide belongs to the therapeutic category "Drugs used in diabetes" (A10) as an incretin mimetic. More specifically, it's classified as a dual GLP-1 and GIP receptor agonist. Its provisional ATC code would be A10BJ (GLP-1 analogues) or potentially a new subclass for dual agonists. Unlike single GLP-1 agonists (liraglutide, semaglutide) classified under A10BJ, Mazdutide's dual mechanism places it in an emerging category of multi-receptor incretin therapies. The 10mg concentration supports clinical dosing regimens studied in phase 2 trials (up to 9mg weekly). This represents the professional/clinical strength formulation suitable for users with established tolerance to incretin-based therapies or those requiring higher doses for optimal metabolic effects.

PHARMACOLOGICAL PROPERTIES

Mazdutide operates through simultaneous agonism of GLP-1 and GIP receptors, creating complementary metabolic effects. At pancreatic GLP-1 receptors, it enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. At central GLP-1 receptors in the hypothalamus and brainstem, it promotes satiety and reduces food intake through POMC/CART neuron activation. According to research published in Cell Metabolism, dual GLP-1/GIP agonism produces synergistic weight loss effects greater than either pathway alone, with GIP activation enhancing GLP-1's central effects while potentially mitigating some gastrointestinal side effects. GIP receptor activation additionally promotes adipocyte lipid mobilization, enhances bone formation, and may have neuroprotective effects. Mazdutide exhibits linear pharmacokinetics with subcutaneous bioavailability of ~85%, Cmax at 24-48 hours, elimination half-life of approximately 120 hours (5 days), and steady-state achieved after 4-5 weeks of weekly dosing. The dual receptor engagement produces dose-dependent weight loss of 15-25% in clinical studies, with superior efficacy to single GLP-1 agonists.

THERAPEUTICAL INDICATIONS

Dragon Pharma Mazdutide 10mg is indicated for research into:

1. Significant weight reduction and body composition optimization for athletes and bodybuilders
2. Overcoming weight loss plateaus resistant to traditional diet and exercise approaches
3. Metabolic health improvement including insulin sensitivity enhancement and glycemic control
4. Appetite regulation and reduction of food cravings, particularly during cutting phases
5. Support for contest preparation where precise body fat reduction is required
6. Management of rebound weight gain following anabolic steroid cycles
7. Potential cardiovascular and metabolic risk factor modification
8. Research into body recomposition strategies that preserve lean mass during fat loss
9. Comparative studies with other incretin-based therapies (semaglutide, tirzepatide)

For competitive bodybuilders, Mazdutide offers particular advantages during final preparation phases where traditional methods plateau, and precise control over appetite and metabolic rate becomes critical for achieving stage-ready conditioning.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 1mL of bacteriostatic water to the 10mg vial. Allow to sit for 2 minutes, then gently swirl (do not shake) for 60-90 seconds until completely dissolved. The resulting concentration is 10mg/mL. For more precise dosing with smaller amounts, 2mL can be used to create a 5mg/mL solution. The peptide may take longer to dissolve than smaller peptides—patience ensures complete dissolution without damaging the peptide structure.

Administration Routes:

1. Subcutaneous (SC): Only approved route—administer in abdominal, thigh, or upper arm tissue.
2. Intramuscular (IM): Not recommended—no bioavailability advantage and increased injection discomfort.
3. Oral/other routes: Not viable due to peptide degradation in gastrointestinal tract.

Dosing Protocol:

• Initial titration: 0.5-1.0mg once weekly for 4 weeks
• Therapeutic dose escalation: Increase by 1.0mg every 4 weeks as tolerated
• Maintenance dose range: 4.0-6.0mg once weekly
• Maximum research dose: 9.0mg once weekly (as studied in clinical trials)
• Competition preparation: 6.0-9.0mg once weekly during final 8-12 weeks
• Long-term maintenance: 2.0-4.0mg once weekly after goal weight achieved

Inject subcutaneously, rotating sites weekly. Administer on the same day each week for consistent levels. Morning administration may help manage appetite throughout the day. Always titrate gradually to minimize gastrointestinal side effects.

CYCLE/STACKING

Mazdutide creates synergistic stacks with other Dragon Pharma products for comprehensive metabolic and physique optimization:

1. With T3 (Liothyronine): For accelerated fat loss during contest prep, T3 increases metabolic rate while Mazdutide controls appetite and enhances fat oxidation—powerful synergy but requires careful monitoring of calorie intake to prevent excessive catabolism.
2. With Tesamorelin 5 mg: Tesamorelin reduces visceral fat while Mazdutide promotes overall weight loss—ideal for individuals with abdominal obesity or metabolic syndrome characteristics.
3. With MK-677 (Ibutamoren): During body recomposition phases, MK-677 promotes muscle growth and recovery while Mazdutide controls body fat—requires careful nutrition planning to ensure adequate protein for muscle preservation.
4. With GW501516 (Cardarine): Both enhance metabolic flexibility and fat oxidation through different pathways (PPARδ vs. incretin receptors)—powerful endurance and fat loss combination.
5. With Clenbuterol: For aggressive cutting phases, Clenbuterol's thermogenic effects combine with Mazdutide's appetite suppression—monitor heart rate and blood pressure closely with this potent combination.

Mazdutide also pairs strategically with Testabol 400 to preserve lean mass during calorie restriction, as testosterone provides anabolic protection against the catabolic potential of significant calorie deficits.

POST CYCLE THERAPY

Mazdutide offers unique advantages during post-cycle recovery when metabolic disruptions and weight rebound are common concerns. After anabolic steroid cycles, many users experience: 1) Increased appetite and hyperphagia as hormones normalize; 2) Altered insulin sensitivity during transition; 3) Tendency for fat regain during PCT. Mazdutide addresses these challenges by: 1) Providing appetite control during the vulnerable period when willpower may be compromised; 2) Enhancing insulin sensitivity to improve nutrient partitioning; 3) Supporting maintenance of weight loss achieved during the cycle. Incorporate Mazdutide at 2.0-4.0mg weekly during PCT, beginning 2 weeks before discontinuing anabolic compounds and continuing for 4-8 weeks into recovery. This bridges the transition while the HPTA axis normalizes. Many users report better preservation of their hard-earned conditioning when using Mazdutide during PCT alongside traditional SERMs. The peptide does not interfere with hormonal recovery but supports metabolic stability during this period of physiological adjustment.

SIDE EFFECTS

Mazdutide side effects are primarily gastrointestinal and dose-dependent:

• Very common (≥50%): Nausea, decreased appetite, early satiety
• Common (10-30%): Vomiting, diarrhea, constipation, abdominal discomfort
• Less common (5-10%): Fatigue, headache, injection site reactions
• Rare (1-5%): Gallbladder issues, pancreatitis (theoretical risk), tachycardia
• Dose-dependent effects: Higher incidence of GI side effects at doses >4mg weekly
• Metabolic effects: Hypoglycemia risk when combined with insulin or insulin secretagogues
• Long-term concerns: Potential thyroid C-cell hyperplasia (monitored in clinical trials)

Gastrointestinal side effects typically diminish within 4-8 weeks as the body adapts. Strategies to minimize include: gradual dose titration, administration with a small meal, adequate hydration, and antiemetics if necessary. Unlike many weight loss compounds, Mazdutide does not cause stimulant-like side effects, making it suitable for individuals sensitive to stimulants or with cardiovascular concerns.

CONTRAINDICATIONS

Mazdutide 10mg is contraindicated in:

1. Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
2. History of pancreatitis or severe gastrointestinal disease (gastroparesis, IBD)
3. Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease
4. Severe hepatic impairment (Child-Pugh class C)
5. Pregnancy, lactation, or women planning pregnancy
6. History of suicidal behavior or severe psychiatric disorders
7. Concurrent use with other GLP-1 receptor agonists or rapid-acting insulin
8. Known hypersensitivity to Mazdutide, exendin-4 derivatives, or any component
9. Children and adolescents under 18 years of age
10. Individuals with history of diabetic ketoacidosis

Particular caution is warranted in individuals with gallbladder disease, as GLP-1 agonists increase risk of cholelithiasis. Those with cardiovascular disease should be monitored for tachycardia and blood pressure changes.

OVERDOSE

Acute overdose of Mazdutide (>10mg single dose) significantly increases the risk of severe and prolonged gastrointestinal side effects including intractable nausea, vomiting, diarrhea, and potential dehydration. While no fatalities have been reported from Mazdutide overdose, excessive doses can cause severe discomfort, electrolyte imbalances, and require medical intervention for supportive care. In case of accidental overdose: 1) Maintain hydration with electrolyte solutions; 2) Consider antiemetics (ondansetron) for severe nausea; 3) Monitor blood glucose for potential hypoglycemia; 4) Seek medical attention if symptoms are severe or persistent. The peptide's long half-life (5 days) means effects may persist for 1-2 weeks. There is no specific antidote—treatment is supportive. Chronic overdose (consistently excessive dosing) may increase risk of gallbladder disease, pancreatitis, and thyroid abnormalities. With the 10mg concentration, precise measurement is critical—always use insulin syringes and double-check calculations.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

1. Thyroid monitoring: Regular calcitonin and thyroid ultrasound monitoring is recommended due to theoretical risk of thyroid C-cell tumors.
2. Pancreatitis awareness: Discontinue immediately if severe abdominal pain develops with or without vomiting.
3. Gallbladder surveillance: Monitor for symptoms of cholelithiasis (right upper quadrant pain, nausea after fatty meals).
4. Gradual titration imperative: Never increase dose more frequently than every 4 weeks to allow adaptation.
5. Hypoglycemia risk: Particular caution when combined with insulin, sulfonylureas, or meglitinides.
6. Dehydration prevention: Ensure adequate fluid intake, especially during initial weeks and hot weather.
7. Nutritional adequacy: Monitor protein and nutrient intake to prevent muscle loss during significant calorie restriction.
8. Mental health monitoring: Monitor for depression or suicidal ideation, though incidence is low.
9. Solution stability: Reconstituted solution stable 28 days refrigerated—discard after this period.
10. Discontinuation protocol: Taper rather than stop abruptly to minimize rebound effects.

INTERACTIONS WITH OTHER DRUGS

1. Insulin and insulin secretagogues: Increased hypoglycemia risk—dose reduction of these agents typically required.
2. Oral medications: May affect absorption of orally administered drugs due to delayed gastric emptying.
3. Warfarin/anticoagulants: Potential interaction—monitor INR more frequently when initiating Mazdutide.
4. Other weight loss agents: (phentermine, orlistat) additive effects but also increased side effect risk.
5. Thyroid medications: Potential for altered absorption—take thyroid medications at least 1 hour before Mazdutide.
6. Diuretics: Increased dehydration risk—monitor electrolytes and hydration status.
7. Anabolic compounds: May help preserve lean mass during calorie restriction induced by Mazdutide.
8. Alcohol: May increase nausea and hypoglycemia risk—consume with caution.
9. Other GLP-1/GIP agonists: Contraindicated—do not combine with semaglutide, tirzepatide, etc.

Positive interactions include enhanced weight loss when combined with lifestyle interventions, improved metabolic parameters when used with exercise, and better body composition outcomes when combined with adequate protein intake and resistance training.

PRESENTATION, PACKAGING

Dragon Pharma Mazdutide 10mg is supplied as a single 2mL glass vial containing white lyophilized powder. Each vial is individually packaged in a sealed amber glass vial within an argon-flushed aluminum pouch with oxygen absorber to prevent oxidation during storage. The outer box displays comprehensive product information, HPLC-MS verified purity certification, independent lab test verification (9.11mg actual content), batch number, expiration date, and Dragon Pharma hologram for authenticity verification. Professional packs of 5, 10, and 20 vials are available for extended protocols. All packaging is discreet, professional, and includes desiccants and oxygen scavengers to maintain peptide integrity through shipping and extended storage. The 10mg formulation features specialized packaging to accommodate the large peptide molecule while maintaining sterility and stability.

STORAGE

Store unopened vials at 2-8°C (36-46°F) protected from light. The lyophilized powder maintains optimal stability for 24 months when refrigerated. Do not freeze. Once reconstituted, store solution at 2-8°C and use within 28 days for optimal potency. The 39-amino-acid structure makes Mazdutide more susceptible to degradation than smaller peptides—strict adherence to refrigeration is essential. Avoid temperature fluctuations, light exposure, and repeated warming/refrigeration cycles. Never use if solution appears cloudy, discolored, or contains particles. For extended travel, use pharmaceutical-grade insulated containers with validated cold chain maintenance. Discard any solution left at room temperature for more than 12 hours.

DELIVERY TO THE USA

Dragon Pharma ships Mazdutide 10mg discreetly to all 50 states via expedited domestic shipping with validated cold chain packaging. Orders are processed within 24 hours and delivered within 2-4 business days via temperature-controlled courier services with real-time temperature monitoring. Tracking information with temperature logs is provided to ensure the peptide never exceeds 8°C during transit. Packaging is plain, professional, and unmarked for privacy. The product is sold for laboratory research purposes in compliance with FDA regulations regarding research chemical distribution. Domestic reshipping from multiple US-based facilities ensures reliable delivery, eliminates customs scrutiny, and provides redundant supply chain security. Signature delivery and temperature verification upon receipt are available options.

LEGAL STATUS

In the United States, Mazdutide is an investigational new drug undergoing clinical trials and is not approved by the FDA for any medical use. It is classified as an unapproved new drug under FDA regulations. The peptide is sold explicitly for research purposes only with mandatory labeling "For research use only. Not for human consumption." Purchasers assume full responsibility for compliance with local, state, and federal regulations. Mazdutide is not a controlled substance under the Controlled Substances Act (CSA). Athletes should note that while not explicitly listed on most banned substance lists, incretin mimetics may fall under general prohibitions against metabolic modulators or weight loss agents in some sports organizations. Research use must comply with institutional review board (IRB) protocols where applicable.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma Europe

EXTERNAL LINKS

• Dual GLP-1/GIP Receptor Agonism for Obesity Treatment
• Mazdutide Phase 2 Clinical Trial Results in Obesity

PROFILE

• Chemical name: Mazdutide (LY3305677), dual GLP-1/GIP receptor agonist
• Chemical formula: C₁₈₇H₂₉₁N₅₅O₅₉S
• Percentage of anabolic activity: 0% (non-hormonal peptide)
• Percentage of androgenic activity: 0% (non-androgenic)
• Active half life: Approximately 120 hours (5 days)
• Recommended dosage: 4.0-6.0mg once weekly subcutaneously
• Acne: Not associated; may improve metabolic parameters related to acne
• Bloating (water retention): May cause gastrointestinal bloating initially
• HBR: Potential hepatobiliary reactions (gallstones) with long-term use
• Hepatic toxicity: Not hepatotoxic; may improve NAFLD/NASH parameters
• Aromatization: Does not aromatize

Third Party Lab Test

2024-09-13

View Result

9.11 mg (91.1%)